Abstract
Ovarian cancer is the fifth most frequent cause of death from oncologic diseases in women. Ovarian cancer is notable for unsatisfactory treatment outcomes due to the asymptomatic course of the disease and, in consequence, late diagnosis. This disease is characterized by rapid growth with subsequent spread to adjacent organs, dissemination through the organs of the small pelvis and abdominal cavity, and extensive lymphogenic and hematogenic metastasis. The probability of tumor recurrence in the third to fourth stages reaches 96% of cases within 6 months to 2 years after the end of primary treatment.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Delbeke D, Martin WH (2001) Positron emission tomography imaging in oncology. Radiol Clin North Am 39:883–917
Drieskens O, Stroobants S, Gysen M et al (2003) Positron emission tomography with FDG in the detection of peritoneal and retroperitoneal metastases of ovarian cancer. Gynecol Obstet Invest 55:130–134
Hubner KF, McDonald TW, Niethammer JG et al (1993) Assessment of primary and metastatic ovarian cancer by positron emission tomography (PET) using 2-[18F]deoxyglucose (2-[18F]FDG). Gynecol Oncol 51:197–204
Kim S, Chung JK, Kang SB et al (2004) [18F]FDG PET as a substitute for second-look laparotomy in patients with advanced ovarian carcinoma. Eur J Nucl Med Mol Imaging 31:196–201
Nanni C, Rubello D, Farsad M et al (2005) (18)F-FDG PET/CT in the evaluation of recurrent ovarian cancer: a prospective study on forty-one patients. Eur J Surg Oncol 31:792–797
Rose PG, Faulhaber P, Miraldi F, Abdul-Karim FW (2001) Positive emission tomography for evaluating a complete clinical response in patients with ovarian or peritoneal carcinoma: correlation with second-look laparotomy. Gynecol Oncol 82:17–21
Schroder W, Zimny M, Rudlowski C, Bull U, Rath W (1999) The role of 18-F-flurorodeoxyglucose position imaging tomography 18-F-FGD PET in ovariancarcinoma. Int J Gynecol Cancer 9:117–122
Smith GT, Hubner KF, McDonald T, Thie JA (1999) Cost analysis of FDG PET for managing patients with ovarian cancer. Clin Positron Imaging 2:63–70
Takekuma M, Maeda M, Ozawa T et al (2005) Positron emission tomography with 18F-fluoro-2-deoxyglucose for the detection of recurrent ovarian cancer. Int J Clin Oncol 10:177–181
Turlakow A, Yeung HW, Salmon AS et al (2003) Peritoneal carcinomatosis: role of (18)F-FDG PET. J Nucl Med 44:1407–1412
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Granov, A., Tiutin, L., Schwarz, T. (2013). Ovarian Cancer. In: Granov, A., Tiutin, L., Schwarz, T. (eds) Positron Emission Tomography. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-21120-1_12
Download citation
DOI: https://doi.org/10.1007/978-3-642-21120-1_12
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-21119-5
Online ISBN: 978-3-642-21120-1
eBook Packages: MedicineMedicine (R0)